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Abstract
Background and Purpose: It is well known that obesity is related to hy-
pertension through several mechanisms, such as sympathetic overactivity
and excess renal sodium reabsorption. Obesity and hypertension may also be
linked by leptin, a peptide that is elevated in obese individuals. Leptin is an
adipocyte derived hormone that acts in hypothalamus to regulate appetite,
energy expenditure and sympathetic nervous system outflow, as well as in
peripheral tissues, such as blood vessels and kidneys. The aim of our research
was to determine plasma leptin in hypertensive and normotensive obese pa-
tients with the same body mass index (BMI) and show a possible difference
between leptin levels in these two groups of patients.
Materials and Methods: The research was carried out on 21 hyperten-
sive and 19 normotensive patients (20 men and 20 women) with BMI in
range 30–35 kg/m2, normal values of fasting plasma glucose, urea and
creatinine. Leptin was determined using Elisa method.
Results and Conclusion: The results showed that men had significantly
higher waist to hip ratio (W/H). Plasma leptin was significantly higher in
hypertensive women as well as in hypertensive men (p=0.03) in relation to
normotensive patients. There was also significant difference in serum crae-
tinine and creatinine clearance between normotensive and hypertensive
women, although creatinine was within normal range. There was a signifi-
cant difference in serum tryglicerides between men and women in general,
where men had higher values (p=0.016). This confirmed that leptin corre-
lates with hypertension in both men and women.
INTRODUCTION
Hypertension and obesity are common risk factors for the develop-ment of cardiovascular diseases, along with diabetes and hyper-
lipidemia. The prevalence of hypertension in developed countries in
Europe is about 44%, while in North America it is about 28% (1). Al-
most a half of hypertensive patients are obese. The prevalence of hyper-
tension in obese individuals is two times higher than in general popula-
tion. Therefore, many studies have been focused on explaining the con-
nection between obesity and hypertension. Adipose tissue is the key
organ for production of cytokines that are possible mediators of obesity
related hypertension (2). One of the cytokines – adipokines that might
have an important role in the pathophysiology of obesity induced hy-
pertension is leptin. It is a 16 kDa protein secreted by adipose tissue (3)
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diture. It is also involved in a number of physiological
processes such as regulation of carbohydrate and lipid
metabolism, gastrointestinal and cardiovascular func-
tion, inflammatory processes, immune function and re-
production (4). Plasma leptin concentration is propor-
tional to the amount of white adipose tissue and it is in-
creased in obese individuals (5). Leptin levels are higher
in women than in men. Leptin is secreted in a circadian
rhythm where morning levels are relatively high in lean
people, the lowest value is obtained at noon and peak val-
ues are obtained in the evening. The evening values are
related to numerous factors like hormones, circadian
rhythm and dynamics of food intake (6).
It is well known that obesity is related to hypertension
as both are factors of metabolic syndrome. Obesity in-
duced hypertension is related to sympathetic overactivity
as well as to excess sodium reabsorption. Leptin is a pos-
sible mediator of obesity-related hypertension since it
acts in the hypothalamus by stimulating sympathetic
nervous system (SNS) centrally, which indirectly causes
vasoconstriction and excess renal sodium absorption (7).
Thus, leptin centrally increases blood pressure and heart
rate (8). Through its systemic actions leptin affects blood
vessels stimulating nitric oxide (NO) production which
leads to vasodilation (9). In the kidney, leptin affects re-
nal tubules to promote natriuresis and dieresis (10). So-
me studies have shown that acute administration of lep-
tin has no effects on blood pressure unless leptin is admi-
nistered directly into the central nervous system (CNS)
(11). Then, only leptin-induced sympathoactivation ta-
kes place and systemic actions of leptin such as NO pro-
duction and natriuresis are not induced. However, chro-
nic administration of leptin leads to a rise in blood pres-
sure (12). Therefore, obesity could be considered a state
of chronic hyperleptinemia with the consequences simi-
lar to those in chronic leptin infusion. Several studies
have shown a positive correlation between leptin and hy-
pertension (13, 14) but the study on Japanese-Brazilian
women suggested that leptin is not independently re-
lated to hypertension in women (15). The aim of our
study was to determine plasma leptin level in hyperten-
sive and normotensive obese patients and show a possi-
ble difference between leptin levels in both groups of pa-
tients, i.e. men and women, using ELISA method.
PATIENTS AND METHODS
The study included twenty-one hypertensive and ni-
neteen normotensive patients (20 male and 20 female).
The signed informed consent was obtained from all sub-
jects. The study included patients with BMI in 30–35
kg/m2 the range. All patients led sedentary lifestyle. Ex-
clusion criteria were elevated serum creatinine and im-
paired glucose metabolism. Hypertensive patients were
taking antihypertensive medications and twenty patients
were taking lipid lowering medications.
Patients were divided into four groups according to
sex and the presence of hypertension. Hypertension was
defined as blood pressure values of 140/90 mmHg or
above measured at least three times separately or as tak-
ing antihypertensive therapy for at least 1 year prior to
the study.
Anthropometric measurements
Weight and height were measured by standard meth-
ods. Waist circumference was measured at the umbilical
level, in the middle between the lowest rib and the iliac
crest. Hip circumference was measured at the trochanter
level. BMI was calculated to confirm the inclusion crite-
rion. Waist to hip ratio (WHR) was calculated as it is the
most useful parameter of obesity and the simplest an-
thropometric parameter for predicting a wide range of
risk factors and related health conditions.
Biochemical analysis
Glucose, creatinine, cholesterol, triglycerides, low den-
sity lipoproteins and high density lipoproteins were de-
termined in serum by standard methods. Patients fasted
for at least 12 hours prior to the procedure. Creatinine
clearance was calculated using Cockcroft-Gault equa-
tion – GFR = (140-age) ´ (weight in kilograms) ´ (0.85
if female) / (72 ´ creatinine).
Leptin determination
Blood samples were taken from all patients between 7
and 7:30 am after the 12 hour fasting period. Plasma
leptin was measured in the meantime using ELISA me-
thod (Leptin ELISA, IBL, Hamburg, Germany). Stan-
dard values for non-obese persons (BMI 18–25 kg/m2)
were 2.05–5.63 ng/mL for men and 3.63–11.09 ng/mL
for women.
Statistical methods
Data are presented as mean ± SD. All statistical tests
were two-sided and carried out to a significance level (p)
of 0.05. Shapiro-Wilks test of normality was used to
analys leptin distribution in all patient groups. Accord-
ing to the results of Shapiro-Wilks test, the obtained val-
ues are equally distributed, therefore we used Student
t-test when checking the statistical significance of the dif-
ference in average leptin values in all groups of patients.
Data were prepared for analysis in Microsoft Excel 2003.
Statistical analysis was made by SPSS 15.0 for Windows
Evaluation Version and Statistica 7.1.
RESULTS
Anthropometric and biochemical data are presented
in Table 1. Waist to hip ratio was significantly higher in
men than in women (p<0.005). Plasma leptin levels
were significantly higher in hypertensive obese patients
than in normotensive obese patients in both genders,
(p=0.031 in women, p=0.031 in men) (Figure 1, 2). The
results also showed statistically significant difference in
creatinine and creatinine clearance between normoten-
sive and hypertensive women (p=0.04 and p<0.001, re-
spectively), but both parameters were within normal ran-
ge. There was no significant difference in triglyceride
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and cholesterol levels in NT and HT subjects regardless
of gender, but triglycerides were significantly higher in
men than in women (p=0.016).
DISCUSSION
The aim of this study was to determine whether there
is significant difference between plasma leptin levels in
hypertensive and normotensive patients with the same
BMI. The results from earlier studies showed strong cor-
relation between leptin and hypertension in humans
suggesting that leptin has a significant role in the pa-
thophysiology of obesity induced hypertension, but some
studies were not able to confirm this association (15). As
previous studies revealed that increased leptin levels
combined with decreased NO production and enhanced
sympathetic activity may contribute to blood pressure el-
evation in the obese (14), this study aimed to verify this
finding once again. Leptin has no effect on blood pres-
sure in healthy eutrophic subjects because it has pressor
and depressor effects that are in constant balance in
healthy individuals (16). Our results indicate that the
balance between those pressor and depressor mecha-
nisms is damaged. The possible explanation is selective
leptin resistance (17) where only pressor effects take
place and depressor effects of leptin are lost. The mecha-
nism of selective leptin resistance has still not been iden-
tified, but theories involve intracellular signalling dis-
ruption and saturable transport across blood-brain bar-
rier (18). Due to selective leptin resistance, the preserved
sympathoactivation causes pressor effects in the kidneys
and blood vessels, thus elevating blood pressure and
leading to further cardiovascular complications.
It should be noted that hypertensive patients in our
study were treated with antihypertensive medications.
Previous studies suggested that antihypertensive agents
have metabolic effects beside blood pressure lowering
such as increasing level of adiponectin and decreasing
leptin. Therefore, the difference between plasma leptin
levels in hypertensive and normotensive patients might
have been greater if there was no influence of antihy-
pertensive medication (19). Also, the difference between
leptin levels in men and women was not as great as ex-
pected, which may be explained by higher WHR in men.
WHR >1 predicts abdominal adiposity but it is still un-
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TABLE 1









No 10 10 11 9
age (years) 57.1±8.35 46.8±12.5 62.45±9.77 43.55±8.81
w/h 1.02±0.02 0.99±0.07 0.89±0.04 0.85±0.07
BMI (kg/m2) 32.05±1.16 31.8±1.36 33.06±1.84 33.22±1.83
cr (mmol/L) 89.8±14.4 89.1±11.56 72.9±13.3 61.55±8.01
crc (mL/s) 1.9±0.39 2.23±0.56 1.64±0.32 2.41±0.4
gl (mmol/L) 5.61±0.52 5.34±0.46 5.41±0.93 4.96±0.51
ch (mmol/L) 5.84±1.08 5.93±0.87 5.56±0.98 5.64±1.19
tg (mmol/L) 2.62±1.88 2.67±1.43 1.47±0.6 1.75±0.84
leptin (ng/mL) 8.022±5.33 3.57±2.74 p=0.031 10.92±4.87 5.93±4.61 p=0.031
Mean ± SD, unless otherwise stated
















Figure 2. Leptin in hypertensive men is significantly higher than













Figure 1. Leptin in hypertensive women is significantly higher than
leptin in normotensive women.
certain whether leptin correlates better with abdominal
or peripheral adiposity.
It is known that ACE inhibitors reduce glomerular fil-
tration by 20 %, which may explain the fact that serum
creatinine was higher while creatinine clearance was
lower in hypertensive women. There was no significant
difference in men. The reason might be the small num-
ber of patients included in the study, which is actually its
major drawback.
The obtained results confirmed the correlation be-
tween plasma leptin level and hypertension. Mechani-
sms for development of selective leptin resistance seem to
be the main leading cause for the development of obesity
related hypertension, and they need to be a subject of fur-
ther research.
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